The unique application of blockchain technology aims to transform biological assets into tradable digital instruments.
Shineco Inc., a biotech company focused on stem cell technology, has partnered with blockchain provider Plus Me Limited to create what they claim is the world’s first on-chain platform for tokenizing cellular assets.
Blockchain technology for the biological assets verification
The platform will use smart contracts and non-fungible digital identifiers (NFDIs) on the Ethereum blockchain to securely rack and verify ownership of compliant cellular assets.
The company will issue “Cell Infusion Redemption Tokens” that can be redeemed for cell therapy services at affiliated centers. This tokenization framework addresses major industry pain points, including high costs, lack of verifiable product provenance, and illiquid asset pools.
Jennifer Zhan, CEO of Shineco, commented:
“Token holders gain governance rights, including future DAO voting to enhance global ecosystem development in cell therapy—fundamentally transforming traditional marketing paradigms.”
Shineco has also acquired a controlling stake in a cell storage company to ensure a complete on-chain and off-chain infrastructure, positioning itself as a global leader in the emerging “decentralized biotech economy.”
